← board
GRTX
distress 7/10 · high distress / dilution risk$16.280%today-22% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
1.2 yrs
Shares 1y
+113%
Price & events
+241.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-1.7%
1W
-5.0%
1M
-14.0%
3M
+226.9%
6M
+223.0%
1Y
-36.7%
2Y
-99.2%
5Y
-99.2%
All
Overview
- Market Cap
- $2.61B
- Volume
- 0
- 52 Week Range
- $3.20 – $20.96
- Total Shares
- 160.43M
- Float Shares
- 287.00K
- Short %
- 4.75%
- Beta
- 2.60
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-04-14partnershipDefinitive merger agreement with Obsidian Therapeutics, concurrent PIPE financing of $350 million.SEC 8-K
- 2024-08-14trial discontinuedBoard approved plan of dissolution and liquidation.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.